Search results for " bronchi"

showing 10 items of 113 documents

Selective Inhibition of Phosphodiesterases 4A, B, C and D Isoforms in Chronic Respiratory Diseases: Current and Future Evidences

2016

Chronic respiratory diseases affect millions of people every day. According to the World Health Organization estimates, ~235 million people suffer from asthma, ~64 million suffer from chronic obstructive pulmonary disease (COPD), and millions more suffer from allergic rhinitis around the world. In recent last years, the first phosphodiesterase 4 (PDE4) inhibitor, roflumilast, was approved as a treatment to reduce the risk of exacerbations in stable and severe COPD associated with chronic bronchitis and a history of exacerbations. PDE4 exists as four subtypes (A, B, C, and D) each with a capacity to degrade cAMP, a second messenger involved in inflammatory responses. PDE4 inhibitors inhibit …

0301 basic medicineChronic bronchitisPhosphodiesterase InhibitorsPharmacologyPulmonary Disease Chronic Obstructive03 medical and health sciencesPDE4BDrug DiscoverymedicineAnimalsHumansRespiratory systemRoflumilastAsthmaPharmacologyCOPDPhosphoric Diester Hydrolasesbusiness.industryPhosphodiesterasemedicine.diseaseIsoenzymesDiarrhea030104 developmental biologymedicine.symptombusinessmedicine.drugCurrent Pharmaceutical Design
researchProduct

Bronchial inflammation and bacterial load in stable COPD is associated with TLR4 overexpression.

2017

Toll-like receptors (TLRs) and nucleotide-binding oligomerisation domain (NOD)-like receptors (NLRs) are two major forms of innate immune sensors but their role in the immunopathology of stable chronic obstructive pulmonary disease (COPD) is incompletely studied. Our objective here was to investigate TLR and NLR signalling pathways in the bronchial mucosa in stable COPD.Using immunohistochemistry, the expression levels of TLR2, TLR4, TLR9, NOD1, NOD2, CD14, myeloid differentiation primary response gene 88 (MyD88), Toll-interleukin-1 receptor domain-containing adaptor protein (TIRAP), and the interleukin-1 receptor-associated kinases phospho-IRAK1 and IRAK4 were measured in the bronchial muc…

0301 basic medicineTIRAPMaleRespiratory SystemVital CapacityHAEMOPHILUS-INFLUENZAELUNG MICROBIOMEPathogenesisPulmonary Disease Chronic Obstructive0302 clinical medicineNOD2ImmunopathologyForced Expiratory VolumeNod1 Signaling Adaptor ProteinNOD1PhosphorylationCOPDSmoking11 Medical And Health SciencesMiddle AgedCPG-DNAbronchial inflammationAnti-Bacterial AgentsStreptococcus pneumoniaePseudomonas aeruginosaMOUSE LUNGFemaleLife Sciences & BiomedicineMoraxella catarrhalisSignal TransductionEXPRESSIONPulmonary and Respiratory MedicineCD14BronchiRespiratory MucosaReal-Time Polymerase Chain ReactionOBSTRUCTIVE PULMONARY-DISEASETLRs NLR bronchial inflammationNLRDENDRITIC CELL SUBSETS03 medical and health sciencesProtein DomainsmedicineHumansTLRsAgedTOLL-LIKE RECEPTORSCOPD TLR4InflammationScience & TechnologyBacteriabusiness.industrymedicine.diseaseHaemophilus influenzaeBacterial Loadrespiratory tract diseasesToll-Like Receptor 4TLR2030104 developmental biology030228 respiratory systemImmunologyINNATE IMMUNITYT-CELLSbusinessThe European respiratory journal
researchProduct

Effects of Infant Formula With Human Milk Oligosaccharides on Growth and Morbidity: A Randomized Multicenter Trial

2017

Objectives:The aim of the study was to evaluate the effects of infant formula supplemented with 2 human milk oligosaccharides (HMOs) on infant growth, tolerance, and morbidity. Methods:Healthy infants, 0 to 14 days old, were randomized to an intact-protein, cow's milk-based infant formula (control, n=87) or the same formula with 1.0g/L 2fucosyllactose (2FL) and 0.5g/L lacto-N-neotetraose (LNnT) (test, n=88) from enrollment to 6 months; all infants received standard follow-up formula without HMOs from 6 to 12 months. Primary endpoint was weight gain through 4 months. Secondary endpoints included additional anthropometric measures, gastrointestinal tolerance, behavioral patterns, and morbidit…

0301 basic medicinesafetyMalePediatricsmedicine.medical_specialtyMEDLINEOligosaccharidesWeight Gainlaw.inventionbronchitis03 medical and health scienceschemistry.chemical_compound2'-FucosyllactoseRandomized controlled trialDouble-Blind Method2fucosyllactose; bronchitis; lacto-N-neotetraose; safety; tolerancelawMulticenter trialmedicineAnimalsHumansLacto-N-neotetraoseRespiratory Tract Infectionslacto-N-neotetraose2′fucosyllactose030109 nutrition & dieteticstoleranceMilk Humanbusiness.industryGastroenterologyOriginal Articles: NutritionInfant Newbornfood and beveragesInfantProtective Factorsmedicine.diseaseInfant Formula030104 developmental biologyMilkchemistryInfant formulaPediatrics Perinatology and Child Health2'fucosyllactose bronchitis lacto-N-neotetraose safety toleranceBronchitisFemalemedicine.symptombusinessWeight gainFollow-Up Studies
researchProduct

15(S)-HETE modulates LTB(4) production and neutrophil chemotaxis in chronic bronchitis.

2000

We evaluated the levels of 15(S)-hydroxyeicosatetraenoic acid [15(S)-HETE] and the expression of 15-lipoxygenase (15-LO) mRNA in induced sputum obtained from 10 control and 15 chronic bronchitis subjects. 15(S)-HETE was evaluated by reverse phase high-performance liquid chromatography separation followed by specific RIA. 15-LO mRNA expression was determined by primed in situ labeling. The levels of both soluble and cell-associated 15(S)-HETE resulted significantly higher in chronic bronchitis than in control subjects. The percentage of cells expressing 15-LO mRNA was significantly higher in chronic bronchitis than in control subjects ( P < 0.01). Double staining for specific cell type ma…

AdultChronic bronchitisPhysiologyLeukotriene B4Cell SurvivalNeutrophilsNeutrophileCell CountLeukotriene B4chemistry.chemical_compoundHydroxyeicosatetraenoic AcidsMedicineArachidonate 15-LipoxygenaseHumansLung Diseases ObstructiveRNA MessengerBronchitisCells CulturedIn Situ HybridizationAgedbiologyIonophoresbusiness.industryMacrophagesSputumChemotaxisCell BiologyMiddle Agedmedicine.diseaseImmunohistochemistryChemotaxis Leukocytemedicine.anatomical_structureEicosanoidchemistryArachidonate 5-lipoxygenaseImmunologyChronic Diseasebiology.proteinBronchitisLeukotriene AntagonistsbusinessRespiratory tractAmerican journal of physiology. Cell physiology
researchProduct

Release of transforming growth factor-beta (TGF-β) and fibronectin by alveolar macrophages in airway diseases

1996

Abstract Asthma and chronic bronchitis are associated with airway remodelling, and airway macrophages are present in bronchial inflammation. TGF-β and fibronectin released by alveolar macrophages possess a fibrogenic potency. The potential role of alveolar macrophages in airway remodelling was studied in asthma and chronic bronchitis by the release of TGF-β and fibronectin. Alveolar macrophages were isolated by bronchoalveolar lavage in 14 control subjects, 14 asthmatics and 14 chronic bronchitics. The spontaneous and lipopolysaccharide (LPS)- or concanavalin A (Con A)-induced release of TGF-β and fibronectin was measured by ELISA. Alveolar macrophages from chronic bronchitics spontaneously…

AdultLipopolysaccharidesMaleChronic bronchitisLipopolysaccharideImmunologyPathogenesischemistry.chemical_compoundFibrosisTransforming Growth Factor betaMacrophages AlveolarConcanavalin AImmunology and AllergyMacrophageMedicineHumansBronchitisbiologymedicine.diagnostic_testbusiness.industryOriginal Articlesrespiratory systemMiddle Agedmedicine.diseaseAsthmarespiratory tract diseasesFibronectinsFibronectinmedicine.anatomical_structureBronchoalveolar lavagechemistryImmunologyChronic Diseasebiology.proteinFemalePulmonary alveolusbusiness
researchProduct

The difference in risk of chronic pulmonary disease morbidity and mortality between former elite athletes and ordinary men in Finland.

2019

The impact of a history of competitive sports on later smoking behaviour and occurrence of chronic pulmonary diseases is poorly known. We investigated how a history of elite level sports predicted later pulmonary disease morbidity and mortality. Chronic pulmonary disease incidence was assessed from national hospital and cause-of-death registers from 1970 to 2015 among Finnish male former elite athletes (n = 2078) and matched controls (n = 1453) alive in 1970 (mean age 45.0 years). Hazard ratios (HRs) were calculated by Cox proportional hazards model. In 1985, cohort members reported on their smoking habits, engagement in physical activity/sports and physician-diagnosed chronic diseases. The…

AdultLung DiseasesMalemedicine.medical_specialtyChronic bronchitisCompetitive Behavior030209 endocrinology & metabolismPhysical Therapy Sports Therapy and RehabilitationComorbidity03 medical and health sciences0302 clinical medicineAge DistributionRisk FactorsInternal medicineCause of DeathmedicineHumansOrthopedics and Sports MedicineLongitudinal StudiesYoung adultExerciseFinlandProportional Hazards ModelsCOPDbiologyAthletesProportional hazards modelbusiness.industryHazard ratioSmoking030229 sport sciencesGeneral MedicineLength of StayMiddle Agedbiology.organism_classificationmedicine.disease3. Good healthSocioeconomic FactorsAthletesCohortChronic DiseasePhysical EndurancebusinessCohort studyEuropean journal of sport science
researchProduct

Long-Term Determinants of Muscle Strength Decline: Prospective Evidence from the 22-Year Mini-Finland Follow-Up Survey

2012

Objectives: To examine long-term changes in handgrip strength and the factors predicting handgrip strength decline. Design: Longitudinal cohort study with 22 years of follow-up. Setting: Population-based Mini-Finland Health Examination Survey in Finland. Participants: Nine hundred sixty-three men and women aged 30 to 73 at baseline. Measurements: Handgrip strength was measured using a handheld dynamometer at baseline and follow-up. Information on potential risk factors, namely lifestyle and chronic conditions, and their changes throughout the follow-up were based on health interviews. Results: Based on linear mixed-effect models, midlife physically strenuous work, excess body weight, smokin…

AdultMaleGerontologyAgingSarcopeniaChronic bronchitisMuscle Strength Dynamometermedicine.medical_specialtyTime FactorsPopulationMuscle Strength DynamometerDiseasePredictive Value of TestsRisk FactorsWeight lossSurveys and QuestionnairesDiabetes mellitusActivities of Daily LivingmedicineHumansMuscle StrengthProspective StudiesProspective cohort studyeducationGeriatric AssessmentFinlandAgededucation.field_of_studyHand Strengthbusiness.industryIncidenceMiddle Agedmedicine.diseaseHealth SurveysMiddle ageDisease ProgressionPhysical therapyFemaleGeriatrics and Gerontologymedicine.symptombusinessFollow-Up StudiesJournal of the American Geriatrics Society
researchProduct

Treatment Monitoring Program for Implementation of Adherence to Second-Line Erlotinib for Advanced Non–Small-Cell Lung Cancer

2012

Abstract Background Adherence to erlotinib could be a determinant for clinical outcome and treatment toxicity in patients with advanced non–small-cell lung cancer (A-NSCLC). Patients and Methods In an observational study, the Basel Assessment of Adherence Scale (BAAS), a visual analogue scale (VAS), pill counting, and missed appointment rate were used to evaluate adherence in a first cohort of patients who was prescribed erlotinib without a specifically designed management strategy and in a second cohort of patients followed by an oral treatment monitoring program. Results Adherence > 95% by BAAS at 2 months of treatment in the first and second cohorts was 72% and 84%, respectively ( P = .0…

AdultMalePulmonary and Respiratory MedicineCancer Researchmedicine.medical_specialtyLung NeoplasmsVisual analogue scaleAdenocarcinomaMedication AdherenceErlotinib HydrochlorideCarcinoma Non-Small-Cell LungInternal medicinemedicineHumansErlotinib HydrochlorideProtein Kinase InhibitorsSurvival rateAgedNeoplasm StagingRetrospective StudiesAged 80 and overSalvage Therapybusiness.industryHealth Plan ImplementationRetrospective cohort studyAdenocarcinoma Bronchiolo-AlveolarMiddle AgedPrognosisSmall Cell Lung CarcinomaMonitoring programConfidence intervalSurgerySurvival RateOncologyCohortQuinazolinesCarcinoma Large CellPatient ComplianceFemaleErlotinibDrug MonitoringbusinessFollow-Up Studiesmedicine.drugClinical Lung Cancer
researchProduct

Guideline-based survey of outpatient COPD management by pulmonary specialists in Germany

2012

Thomas Glaab1,2, Claus Vogelmeier3, Andreas Hellmann4, Roland Buhl11Department of Respiratory Diseases III, Medical Center of the Johannes Gutenberg-University, Mainz, 2Medical Affairs Germany, Respiratory Medicine, Boehringer Ingelheim Pharma GmbH and Co, KG, Ingelheim, 3Department of Respiratory Diseases, University Hospitals of Giessen and Marburg, Marburg, 4Federal Association of Pneumologists, Augsburg, GermanyBackground: Little is known about the role of guidelines for the practical management of chronic obstructive pulmonary disease (COPD) by office-based pulmonary specialists. The aim of this study was to assess their outpatient management in relation to current guideline recommenda…

AdultMaleSpirometryHealth Knowledge Attitudes Practicemedicine.medical_specialtyChronic bronchitisAttitude of Health Personneldiagnosismedicine.medical_treatmentInternational Journal of Chronic Obstructive Pulmonary DiseasePulmonary Disease Chronic ObstructivePatient Education as TopicAmbulatory careRisk FactorsGermanySurveys and QuestionnairesHealth careAmbulatory CaremedicineHumanssurveyPulmonary rehabilitationGOLDPractice Patterns Physicians'Referral and ConsultationOriginal ResearchtherapyCOPDEvidence-Based Medicinemedicine.diagnostic_testbusiness.industryGeneral MedicineGuidelineMiddle Agedmedicine.diseasepulmonary rehabilitationclinical outcomesObstructive lung diseaseRespiratory Function TestsBenchmarkingCross-Sectional StudiesHealth Care SurveysFamily medicinePractice Guidelines as TopicFemaleGuideline AdherencebusinessInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Primary pulmonary sarcomas: Etiology, clinical assessment and prognosis with a comparison to pulmonary carcinomas —A review of 41 cases and 394 other…

1982

Primary sarcomas of the lungs occur at frequencies of 1:100, as compared with carcinomas reported in our retrospective studies covering 394 cases reported in the literature from 1957 to 1972 and 41 cases from 1957 to 1974. The average age was 45 years, the disease usually occurred between the ages of 35 and 65, the peak being between 45 and 60 years. Distribution between sexes was much the same as that seen in general. X-ray with rapid thoracotomy provided the best clinical results. The literature showed a postoperative survival time of 5 years in 19% and 44% of our own cases. The general metastasis, haematologenous and lymphogenous were more or less equal and recidive tendency in 7% essent…

AdultMalemedicine.medical_specialtyChronic bronchitisPathologyLung NeoplasmsAdolescentmedicine.medical_treatmentGastroenterologyMetastasisJapanInternal medicinemedicineCarcinomaHumansThoracotomyChildAgedbusiness.industryIncidence (epidemiology)CarcinomaSmokingAge FactorsInfantSarcomaRetrospective cohort studyGeneral MedicineMiddle AgedPrognosismedicine.diseaseChild PreschoolEtiologyFemaleSurgerySarcomabusinessThe Japanese Journal of Surgery
researchProduct